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Background: The aim of this study was to define the independent determinants of left atrial appendage (LAA)
thrombus among various echocardiographic parameters measured by Velocity Vector Imaging (VVI) in patients with
nonvalvular atrial fibrillation (AF) receiving warfarin, particularly in patients with a low CHADS2 score.
Methods: LAA emptying fraction (EF) and LAA peak longitudinal strain were measured by VVI using
transesophageal echocardiography in 260 consecutive patients with nonvalvular persistent AF receiving warfarin.
The patients were divided into two groups according to the presence (n=43) or absence (n=217) of LAA thrombus.
Moreover, the patients within each group were further divided into subgroups according to a CHADS2 score ≤1.
Results: Multivariate logistic regression analysis showed that LAAEF was an independent determinant of LAA
thrombus in the subgroup of 140 with a low CHADS2 score. Receiver operating characteristics curve analysis
showed that an LAAEF of 21% was the optimal cutoff value for predicting LAA thrombus.
Conclusions: LAA thrombus formation depended on LAA contractility. AF patients with reduced LAA contractile
fraction (LAAEF ≤21%) require strong anticoagulant therapy to avoid thromboembolic events regardless of a low
CHADS2 score (≤1).
Keywords: Atrial fibrillation, Left atrial appendage, Thrombus, Transesophageal echocardiographyLeft atrial appendage (LAA) thrombus in patients with
atrial fibrillation (AF) is a high risk factor of cardiogenic
thromboembolism, and causes stroke at the rate of 1.5 -
3.4% per year even in patients receiving warfarin [1-3].
Establishment of optimal risk stratification and thera-
peutic strategies is the best hope for decreasing the bur-
den of AF-related thromboembolism. The international
normalized ratio of prothrombin time (PT-INR) is used
as an index for optimal anticoagulation therapy, and the
CHADS2 (congestive heart failure, hypertension, age
≥75 years, diabetes mellitus, and prior stroke or transient
ischemic attack) score is widely used for risk stratification* Correspondence: masanori@ya2.so-net.ne.jp
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reproduction in any medium, provided the orof thrombus in clinical practice [4,5]. However, it was
reported that some AF patients that have PT-INR within
the therapeutic range or a low CHADS2 score still suffer
from thromboembolism [6].
As for ultrasound parameters, spontaneous echo con-
trast (SEC) and LAA peak emptying flow velocity
(LAAPV) have been proposed as echocardiographic pre-
dictors of LAA thrombus [7,8]. However, the optimal
cutoff values of ultrasound parameters to predict inci-
dence of LAA thrombus with high sensitivity and speci-
ficity have not been established. Velocity Vector Imaging
(VVI) has been recently developed based on speckle
tracking to evaluate left ventricular function, and this
method can be applied to evaluate left atrial (LA) and
LAA contractile fraction [9-11]. Thus, the aim of thisd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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We performed transthoracic echocardiography (TTE)
and transesopageal echocardiography (TEE) in 300 con-
secutive patients with warfarin therapy that had per-
sistent AF for more than one month to evaluate
intracardiac thrombus, the severity of aortic or mitral
valve stenosis or regurgitation or congenital heart dis-
ease. Persistent AF was documented electrocardiogra-
phically by Holter monitor. There were 37 patients
excluded from the study because of mitral stenosis or
moderate-to-severe mitral regurgitation or previous mi-
tral valve operation. Three patients were excluded be-
cause of poor echocardiographic recordings. The final
analysis included 260 patients with nonvalvular persist-
ent AF that were already receiving warfarin. We divided
those patients into two groups according to the presence
or absence of LAA thrombus. Moreover, each group was
divided into subgroups according to a CHADS2 score
≤1 (low CHADS2 subgroup with LAA thrombus and
without LAA thrombus) [5]. All patients were on war-
farin as an anticoagulant to prevent thromboembolism
according to the Japanese Circulation Society guidelines
for pharmacotherapy of AF [12]. The PT-INR in all
patients was measured one month before and at the
time of TTE and TEE. The average of the two PT-INR
measurements was used for analysis. LAA thrombus was
defined as an echo-dense mass of more than 2 mm in
diameter attached to the LAA wall that could be distin-
guished from the surrounding endocardium or pectinate
muscles. The experimental protocol was approved by
the ethics committee of our institution and informed
consent was obtained from all patients.
Echocardiography
TTE and TEE were performed using an ACUSON Sequoia
512 ultrasound system (Siemens, Mountain View, CA) to
evaluate LAA structure and contractile fraction. We exa-
mined the differences in echocardiographic parameters
between patients with and without LAA thrombus. The
parameters were obtained according to the standards of the
American Society of Echocardiography [13,14]. For TEE, a
4-7 MHz multi-plane transducer with a 7.4 mm diameter
pediatric probe was used to diminish patient discomfort as
previously described [15]. A time-LAA volume curve and a
time-LAA strain curve can be automatically and promptly
provided during a single cardiac cycle by VVI with feature-
tracking echocardiography using off-line software (SyngoVelocity Vector Imaging, Siemens, Mountain View, CA)
(Figure 1). We measured LAA volume by two-dimensional
TEE three times at three different angles (50, 70 and 90
degrees) and used average values for further analysis to
improve the accuracy of the LAA volume measurement, as
we previously reported in detail [11]. Average values of
three cardiac cycles [(maximum volume – minimum vo-
lume)/maximum volume × 100] were used as LAA emp-
tying fraction (EF). LAA volumes were determined using
Simpson’s method. Although an autopsy study reported
that the LAA is usually a multilobed structure [16], Cardiac
computed tomography or magnetic resonance tomography
revealed that in 97% of patients, the LAA in vivo was
shaped like a cactus (30%), chicken wing (48%) or wind-
sock (19%) [6]. Since three-dimensional TEE showed that
the shape of LAA was round throughout the cardiac cycle
in the present study, it was considered reasonable to
measure LAA volume using the disk summation method
(Figure 2). Furthermore, LAAPV, SEC score (grade 0 - 4),
LA dimension (LAD) and left ventricular (LV) ejection
fraction were measured by the same methods as previously
reported [5,11,17]. Excellent reproducibility and reliability
of the VVI measurements were demonstrated in previous
studies [9-11].
Statistical analyses
Data for continuous variables were expressed as the mean ±
one standard deviation. Categorical data were summa-
rized as percentages and compared using a Chi-square
test or a Fisher’s exact test as appropriate. Comparisons
of echocardiographic parameters between main groups
and between subgroups were performed by an unpaired
Student’s t-test. Comparisons of SEC, CHADS2 score
between groups were performed by a Mann–Whitney
U-test. The optimal cutoff values for the determination of
sensitivity and specificity of the echocardiographic para-
meters to determine LAA thrombus were obtained from
receiver operating characteristic (ROC) curve analysis.
Multivariate logistic regression analysis was performed to
identify the independent determinants of LAA thrombus.
Multivariate logistic regression analysis was performed
using clinical variables with a p value ≤0.10 in univariate
analysis to determine the independent predictors of LAA
thrombus. A p-value <0.05 was considered significant.
Statistical analyses were performed using Stat View ver-
sion 5.0 (SAS Institute Inc, Cary, NC, USA).
Results
Patient characteristics
Of the 260 patients with persistent AF included in the
present study, 43 patients had LAA thrombus and 217
did not have LAA thrombus. The clinical characteristics
of all patients are listed in Table 1. In the patients with a
low CHADS2 score (≤1), 15 patients had LAA thrombus
*A B
C
Figure 1 Representative images of the left atrial appendage, and time-volume curve and time-strain curves constructed by velocity
vector imaging in patients with atrial fibrillation. (A) Left atrial appendage (LAA) of a patient without thrombus. (B) LAA of a patient with
thrombus. (C) Time-volume curve is shown as an orange line. Time-dv/dt curve is shown as a blue line. *thrombus. Bar=1 cm.
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were no significant differences in PT-INR, gender, age,
history of smoking, history of diabetes mellitus, history
of hypertension and duration of AF between the groups
with and without LAA thrombus. The target PT-INR
levels were 1.6 - 2.6 for patients aged ≥70 years old and
2.0 - 3.0 for patients aged <70 years old, according to
the guideline of the Japanese Circulation Society. The
target PT-INR was achieved in 31 (73%) of the 43
patients with LAA thrombus, and in 132 (61%) of the
217 patients without LA thrombus. There was noEnd diastole Mid sy
Figure 2 Three-dimensional view of the left atrial appendage at end
white arrow in (A) in Figure 1.significant difference in the number of patients that
achieved the target PT-INR between the two groups (p =
0.16). The target PT-INR was also achieved in 74% of
109 patients aged ≥70 years old and 50% of 151 patients
aged <70 years old. The target PT-INR was achieved in a
greater percentage of the patients aged ≥70 years old
than in the patients aged <70 years old (p <0.001).
Echocardiographic parameters
It took approximately one minute (60 ± 10 seconds) to
obtain LAAEF and LAA longitudinal strain by VVI. Thestole End systole
diastole, mid systole and end systole from a site indicated by the
Table 1 Patient characteristics and echocardiographic parameters in 260 persistent AF patients
AF without thrombus AF with thrombus p-value
(n = 217) (n = 43)
Clinical parameters
Age (year) 65.9 ± 10.5 68.9 ± 9.7 0.08
Male, n (%) 165 (76) 35 (81) 0.41
Smoking, n (%) 51 (23) 10 (23) 0.98
Diabetes Mellitus, n (%) 45 (21) 13 (30) 0.17
Hypertension, n (%) 128 (59) 31 (72) 0.10
Dyslipidemia, n (%) 59 (27) 7 (16) 0.13
Prior stroke, n (%) 25 (12) 11 (26) 0.015
AF duration (year) 5.9 ± 5.8 7.1 ± 5.9 0.22
PT-INR 1.89 ± 0.47 1.91 ± 0.44 0.81
PT-INR met guideline 132 (61) 31 (72) 0.16
CHADS2 score 1 (1 – 2) 2 (1 – 3) 0.003
Echocardiographic parameters
LVEF (%) 57.7 ± 9.2 55.7 ± 9.0 0.19
LAD (mm) 46.7 ± 6.5 49.0 ± 6.1 0.032
Maximum LAA volume (ml) 10.6 ± 4.7 17.4 ± 9.9 <0.001
Minimum LAA volume (ml) 7.4 ± 3.8 14.2 ± 8.4 <0.001
SEC score (0-4 grade) 1 (1 – 1) 1 (1 – 2) <0.001
LAAPV (cm/sec) 29.6 ± 11.4 21.2 ± 6.6 <0.001
LAA peak longitudinal strain 8.2 ± 5.0 2.7 ± 1.9 <0.001
LAAEF (%) 31.3 ± 10.5 18.5 ± 4.2 <0.001
Numerical data are expressed as the mean ± one standard deviation. Non-parametric data are expressed as the median (interquartile range). AF: atrial fibrillation.
PT-INR: prothrombin-international normalized ratio. LAD: left atrial dimension. LVEF: left ventricular ejection fraction. SEC: spontaneous echo contrast. LAAPV: left
atrial appendage peak flow velocity. LAAEF: left atrial appendage emptying fraction.
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compared with that in patients without LAA thrombus
(Table 1). The LAAEF and LAA peak longitudinal strain
in patients with LAA thrombus were significantly
reduced compared with the corresponding values in
patients without LAA thrombus (Table 1). The LAAEF
and LAA peak longitudinal strain in the two subgroup
with LAA thrombus and a low CHADS2 (Table 2) score
were also reduced compared with the corresponding
values in the two subgroups without LAA thrombus and
a low CHADS2 score.
Determinants of LAA thrombus
We performed multivariate analysis using three models
to identify the independent determinants of LAA
thrombus in the patients with a low CHADS2 score:
Model 1 included only clinical variables with a p value
≤0.10 in univariate analysis: Model 2 included conven-
tional echocardiographic parameters (SEC and LAAPV):
and Model 3 included conventional and VVI echocar-
diographic parameters (SEC, LAAPV and LAAEF). How-
ever, LAA peak longitudinal strain was excluded from
Model 3 because there was a strong correlation betweenLAA peak longitudinal strain and LAAEF (r = 0.80,
p < 0.001). The multivariate logistic regression analysis
showed that LAAEF was an independent determinant of
LAA thrombus in the patients with a low CHADS2
score (≤1) (Table 3).
Using an LAAEF of 21% as the cutoff value, ROC
curve analysis showed that the sensitivity was 93%, the
specificity was 96% and the area under the curve (AUC)
was 0.97. Using an LAAPV cutoff value of 24 cm/sec,
the sensitivity was 73%, the specificity was 75% and the
AUC was 0.73 (Figure 3). The sensitivities, specificities,
positive predictive values and negative predictive values
at the optimal cutoff values are listed in Table 4.
Discussion
The present study demonstrated that LAAEF assessed
by VVI was an independent determinant of LAA
thrombus. Since the association between these para-
meters and LAA thrombus were independent of other
clinical and echocardiographic parameters, LAAEF may
be useful for thromboembolic risk stratification. AF
patients with reduced LAAEF (≤ 21%) may require
stronger anticoagulant therapy than patients with
Table 2 Patient characteristics and echocardiographic parameters in 140 persistent AF patients with a low CHADS2
score (≤1)
AF without thrombus AF with thrombus p-value
(n = 125) (n = 15)
Clinical parameters
Age (year) 62.1 ± 9.6 65.3 ± 9.0 0.23
Male, n (%) 93 (74) 12 (80) 0.64
Smoking, n (%) 21 (17) 5 (33) 0.16
Diabetes Mellitus, n (%) 9 (7) 1 (7) >0.99
Hypertension, n (%) 56 (45) 10 (67) 0.11
Dyslipidemia, n (%) 27 (21) 1 (7) 0.30
CHADS2 score = 1 88 (71) 14 (93) 0.059
AF duration (year) 5.9 ± 5.7 6.3 ± 3.4 0.83
PT-INR 1.89 ± 0.49 1.84 ± 0.35 0.65
PT-INR met guideline, n (%) 68 (54) 11 (73) 0.18
Echocardiographic parameters
LVEF (%) 59.1 ± 6.6 57.3 ± 4.8 0.29
LAD (mm) 46.0 ± 6.7 49.5 ± 7.5 0.064
Maximum LAA volume (ml) 10.2 ± 4.7 17.9 ± 8.1 <0.001
Minimum LAA volume (ml) 7.0 ± 3.8 14.8 ± 7.1 <0.001
SEC score (0-4 grade) 1 (1 – 1) 1 (1 – 2) 0.047
LAAPV (cm/sec) 31.9 ± 12.2 23.0 ± 8.3 0.007
LAA peak longitudinal strain 9.3 ± 5.6 2.5 ± 1.5 <0.001
LAAEF (%) 33.5 ± 10.7 17.9 ± 3.6 <0.001
Abbreviations as in Table 1.
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their CHADS2 score is low.
LAA thrombus in patients with a low CHADS2 score
Thromboembolic events related to AF result in signi-
ficant morbidity and mortality. However, the risk ofTable 3 Age adjusted multivariate logistic regression
analysis for LAA thrombus 140 persistent AF patients
with a low CHADS2 score (≤1)
Odds ratio 95% Confidence interval p-value
Variables (Model 1)
Hypertension 1.771 0.851 – 3.686 0.13
Prior stroke 2.409 1.037 – 5.597 0.041
Variables (Model 2)
SEC 1.440 0.730 – 2.843 0.29
LAAPV (cm/sec) 0.931 0.871 – 0.996 0.038
Variables (Model 3)
SEC 0.864 0.335 – 2.226 0.76
LAAPV (cm/sec) 0.954 0.862 – 1.055 0.36
LAAEF (%) 0.570 0.415 – 0.783 <0.001
Abbreviations as in Table 1.thromboembolic events is quite variable [18-21]. A
higher CHADS2 score [3-6] is associated with an
increased risk of systemic embolism, bleeding and death
in patients with AF receiving oral anticoagulants [22].
However, the CHADS2 score may not always be a good
predictor of stroke risk, especially in intermediate risk
patients and patients with relatively low scores [13]. A
previous study reported that 10% of persistent AF
patients had LAA thrombus confirmed by TEE prior to
catheter ablation despite an average PT-INR of 1.9 ± 0.5,
and 77% of the patients with LAA thrombus had a
CHADS2 score ≤2 [23]. In the present study, LAA
thrombus was found in 15/140 (10.7%) patients with a
CHADS2 score ≤1. Among all of the patients, LAA
thrombus was found in 16.5%. This may be due to the
fact that target PT-INR level was achieved only in the
two thirds of the patients. However, this high rate of
LAA thrombus in the present study was concordant
with that in a previous study (15.6%) [24]. Some patients
with AF that receiving warfarin and had a CHADS2
score ≤1 suffered from cerebral embolism because war-
farin was not totally effective in preventing LAA
thrombus, despite a PT-INR in the target range. There-
fore, better risk stratification is needed to improve the














AUC = 0.97 AUC = 0.73
24 cm/sec
LAA emptying function 
Figure 3 Receiver operating characteristic curves for the prediction of left atrial appendage thrombus in 140 persistent atrial
fibrillation patients with low CHADS2 score (≤1). LAA: left atrial appendage, AUC: Area under the curve.
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lant therapy to prevent stroke.
TEE is known as the most sensitive and specific tool to
assess LAA contractile fraction and detect LAA thrombus
[17,23]. Daniel et al. suggested that TEE was associated
with an acceptable low risk when performed by expe-
rienced operators under safe conditions [25]. In addition,
we used a pediatric probe to minimize patient discomfort
under safe conditions, as previously described [15]. Multi-
variate analysis in the present study showed that the asso-
ciation between LAA thrombus and LAA contractility
was stronger than the association between LAA thrombus
and age, hypertension and prior stroke. A recent TEE
study demonstrated that increased LA volume and lower
LV ejection fraction were significant predictors of LAA
thrombus [24]. However, LAA motion was not considered
in this recent study. The present study suggested that an
LAAEF cutoff value of 21%, as measured by VVI echocar-
diography, should be used in a future prospective study to
predict AF-related thrombus. Performing TEE in patients
with a low CHADS2 score is controversial. However, our
results suggest that evaluation of LAAEF by TEE is im-
portant, despite discomfort during the procedure because
of the risk of cerebral infarction due to thromboembolism.Table 4 Accuracy of echo parameters for the
determinants of LAA thrombus in 140 persistent AF
patients with a low CHADS2 score (≤1)
Cutoff values Sensitivity Specificity PPV NPV
LAAPV (≤ 24 cm/sec) 73 (66–80) 75 (68–82) 26 (18–33) 96 (92–99)
LAAEF (≤ 21%) 93 (89–97) 96 (92–99) 74 (67–81) 99 (97–100)
Data are percentages. Numbers in parentheses are 95% confidence intervals.
PPV: positive predictive value. NPV: negative predictive value. Other
abbreviations as in Table 1.Study limitations
There are several limitations of the present study. First,
our findings are based on an observational study with a
relatively small number of patients, particularly in the
patients with both AF and LAA thrombus. We cannot
draw conclusions regarding long-term outcomes, be-
cause the present study was a cross-sectional study. A
prospective study in a lager patient population is needed
to validate the predictive value of LAAEF and LAA peak
strain on long-term outcomes. The predictive accuracy
of the selected cutoff value for LAAEF and strain needs
to be tested prospectively in an independent population
to confirm its ability to predict LAA thrombus. Second,
it is possible that the incidence of LAA thrombus does
not always predict the occurrence of thromboembolic
events because thromboembolism may be affected by
other factors such as age, hypertension and diabetes
mellitus. Finally, we measured the PT-INR levels one
month before and at the time of TTE and TEE and aver-
aged the two measurements. However, we recognized
that there could be disparity between the measurements,
and average value may not provide an accurate index of
blood coagulability during this one-month period. In
general, accurate evaluation of the blood coagulability
was not possible.
Conclusions
LAAEF in AF patients with thrombus was reduced com-
pared with the values in those without thrombus, and
this parameter was an independent determinant of LAA
thrombus among various clinical and echocardiographic
parameters, even in patients with a low CHADS2 score.
AF patients with reduced LAAEF may require stronger
anticoagulant therapy than patients with LAAEF >21%
Ono et al. Cardiovascular Ultrasound 2012, 10:50 Page 7 of 8
http://www.cardiovascularultrasound.com/content/10/1/50to avoid thromboembolic events, even if they have a low
CHADS2 score.
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